(Q44048667)

English

A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.

scientific article published in November 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 November 2017

A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. (English)

1 reference

Europe PubMed Central

29 November 2017

clinical oncology

1 reference

based on heuristic

inferred from title

author name string

Tomohiro Kinoshita

1

1 reference

Europe PubMed Central

29 November 2017

Tomomitsu Hotta

2

1 reference

Europe PubMed Central

29 November 2017

Kensei Tobinai

3

1 reference

Europe PubMed Central

29 November 2017

Tohru Kobayashi

4

1 reference

Europe PubMed Central

29 November 2017

Naoki Ishizuka

5

1 reference

Europe PubMed Central

29 November 2017

Masao Tomonaga

6

1 reference

Europe PubMed Central

29 November 2017

Toshiaki Sai

7

1 reference

Europe PubMed Central

29 November 2017

Youichiro Ohno

8

1 reference

Europe PubMed Central

29 November 2017

Masaharu Kasai

9

1 reference

Europe PubMed Central

29 November 2017

Michinori Ogura

10

1 reference

Europe PubMed Central

29 November 2017

Chikara Mikuni

11

1 reference

Europe PubMed Central

29 November 2017

Hironobu Toki

12

1 reference

Europe PubMed Central

29 November 2017

Masayuki Sano

13

1 reference

Europe PubMed Central

29 November 2017

Yasufumi Masaki

14

1 reference

Europe PubMed Central

29 November 2017

Tomoko Ohtsu

15

1 reference

Europe PubMed Central

29 November 2017

Yoshihiro Matsuno

16

1 reference

Europe PubMed Central

29 November 2017

Takeaki Takenaka

17

1 reference

Europe PubMed Central

29 November 2017

Shigeru Shirakawa

18

1 reference

Europe PubMed Central

29 November 2017

Masanori Shimoyama

19

1 reference

Europe PubMed Central

29 November 2017

Japan Clinical Oncology Group

20

1 reference

Europe PubMed Central

29 November 2017

publication date

1 November 2004

1 reference

Europe PubMed Central

29 November 2017

International Journal of Hematology

1 reference

Europe PubMed Central

29 November 2017

80

1 reference

Europe PubMed Central

29 November 2017

4

1 reference

Europe PubMed Central

29 November 2017

341-350

1 reference

Europe PubMed Central

29 November 2017

https://scigraph.springernature.com/pub.10.1532/ijh97.04085

0 references

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-escalation of CHOP in non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hemato

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Average relative dose intensity and the impact on design of clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody therapy for B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15615259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1532/IJH97.04085

1 reference

Europe PubMed Central

29 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44048667&oldid=2105988975"